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Abstract
Background: Werner syndrome (WS) results from defects in the RecQ helicase (WRN) and is characterized by premature
aging and accelerated tumorigenesis. Contradictorily, WRN deficient human fibroblasts derived from WS patients show a
characteristically slower cell proliferation rate, as do primary fibroblasts and human cancer cell lines with WRN depletion.
Previous studies reported that WRN silencing in combination with deficiency in other genes led to significantly accelerated
cellular proliferation and tumorigenesis. The aim of the present study was to examine the effects of silencing WRN in p53
deficient HL60 and p53 wild-type TK6 hematopoietic cells, in order to further the understanding of WRN-associated
tumorigenesis.
Methodology/Principal Findings: We found that silencing WRN accelerated the proliferation of HL60 cells and decreased
the cell growth rate of TK6 cells. Loss of WRN increased DNA damage in both cell types as measured by COMET assay, but
elicited different responses in each cell line. In HL60 cells, but not in TK6 cells, the loss of WRN led to significant increases in
levels of phosphorylated RB and numbers of cells progressing from G1 phase to S phase as shown by cell cycle analysis.
Moreover, WRN depletion in HL60 cells led to the hyper-activation of homologous recombination repair via up-regulation of
RAD51 and BLM protein levels. This resulted in DNA damage disrepair, apparent by the increased frequencies of both
spontaneous and chemically induced structural chromosomal aberrations and sister chromatid exchanges.
Conclusions/Significance: Together, our data suggest that the effects of WRN silencing on cell proliferation and genomic
instability are modulated probably by other genetic factors, including p53, which might play a role in the carcinogenesis
induced by WRN deficiency.
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Introduction
Werner syndrome helicase (WRN), the protein defective in
Werner syndrome (WS) patients [1], belongs to the RecQ family of
helicases, which are conserved from Escherichia coli to humans [2].
WRN has been shown to interact physically and functionally with
a number of cellular proteins, subsequently involving it in many
aspects of DNA metabolic processes including DNA repair,
recombination, transcription and replication [3,4,5,6]. WS carries
an enhanced risk of neoplasmas of mesenchymal origin [7,8].
Recent work has indicated that the role of WRN in human
pathogenesis may be much broader than envisaged before, and
goes beyond the WS. The polymorphisms of WRN gene is
associated with increased risks of cancer development, including
but not limit to breast, gastric adenocarcinoma and bone and soft
tissue sarcomas [9,10,11,12]. In addition, WRN gene is inactivated
by methylation in a large fraction of common sporadic epithelial
malignancies [13]. Understanding how the WRN deficiency leads
to a rapid heritable and sporadic carcinogenesis thus becomes a
critical task relevant to the new forms of treatment and prognosis
of cancer.
WRN has been suggested to be the ‘‘caretaker’’ of the genome
[14], as its absence in WS patients leads to increased genomic
instability and predisposition to cancer. Interestingly however,
studies have continuously found that WRN deficient human
fibroblasts derived from WS patients show a characteristically
slower cell proliferation rate [15,16]. Acute depletion of WRN in
primary fibroblasts [17] and human cancer cell lines [18] led to
marked growth inhibition. These contradictory observations that
WRN loss in WS patients leads to increased and accelerated
tumorigenesis while cells with WRN deficiency inhibit tumor cell
growth suggests a complex role for WRN in tumorigenesis.
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We recently reported that cellular proliferation is significantly
accelerated after silencing WRN in p53 null hematopoietic HL60
cells [19], providing support for the idea that the loss of WRN
could lead to rapid growth and hence tumorigenesis in certain
situations. This was supported by the findings from wrn-knockout
mice studies in which knockout of wrn alone did not lead to WS
phenotype while crossing wrn-knockout mice with p53-null mice or
mice carrying a null mutation in the terc gene, resulted in classic
WS phenotypes: premature death, rapid tumorigenesis, etc.
[20,21,22,23].
The aims of the present study were to further examine the
biological effects of silencing WRN in HL60 cells, as well as in p53
wild-type hematopoietic TK6 cells. As reported here, silencing
WRN in HL60 cells stimulates RB phosphorylation, driving cells
from G1 to S phase and accelerating proliferation. We further
demonstrate that WRN depletion leads to hyper-activated
homologous recombination repair via up-regulation of RAD51
and BLM, which in turn results in DNA damage disrepair and
chromosomal aberrations. These effects are not observed in TK6
cells deficient in WRN, indicating that differences in the status of
p53 or other factors between these two cell types might play a role
in the carcinogenesis induced by WRN deficiency. This suggests
that the effects of WRN deficiency on cell proliferation and
genomic instability are modulated by other factors.
Results
The depletion of WRN by shRNA has different effects on
the cell proliferation rates of HL60 and TK6 cells
To investigate the effects of silencing WRN in human
hematopoietic cells, we used lentiviral-based vectors to knock
down the protein WRN in both HL60 and TK6 cells (Figure. 1A)
with modification from Ren et al, 2009 [19]. The expression of
WRN protein was significantly reduced by more than 90% in the
HL60 sh-WRN cells and by approximately 75% in the TK6 sh-
WRN cells (Figure. 1B). HL60 sh-WRN cells displayed a
significantly accelerated proliferation rate over seven days of
culture compared to control HL60 sh-NSC cells as evidenced by
the greater than 2.5 fold increase of total cell number by the end of
the culturing period (Figure. 1C) [19]. In contrast, the proliferation
rate of TK6 sh-WRN cells was slightly decreased such that the
resultant total cell numbers were about 30% less than the control
TK6 sh-NSC cells (Figure. 1D). The growth characteristics of the
control cells remained unaltered by the non-silencing shRNA in
both cell types (Data not shown).
Accelerated proliferation rate in HL60 cells is associated
with an increased fraction of cells in S-phase partially due
to RB-hyperphosphorylation
Given the altered proliferation pattern between HL60 and TK6
cells, we measured levels of key proteins in p53 regulated G1/S
phase cell cycle checkpoint pathway. As expected, neither total nor
phosphorylated p53 protein, were detected in the control and
WRN deficient HL60 cells, and p21 protein levels remained
consistently low (Figure. 2A). However, levels of phosphorylated
RB (cRB) were significantly increased in WRN deficient HL60
cells compared to the control HL60 cells. RB serves as the
gatekeeper for progression through the proliferation restriction
point (R point) of the cell cycle [24], blocking progression in its
hypophosphorylated state. Hyperphosphorylation of RB, together
with other factors, allows G1-S progression, and increases the rate
of cell proliferation. Examination of the levels of cyclin D/CDK4
and cyclin E/CDK2, thought to be responsible for the phosphory-
lation of RB, revealed higher levels only of cyclin D3 in HL60
sh-WRN cells compared to control cells, with CDK2, CDK4 and
cyclin E remaining unaltered (Figure. 2A). In contrast, the levels of
phosphorylated p53, as well as p21 were slightly increased, and
subsequently resulted in decreased E2F1 level in TK6 sh-WRN
cells compared to TK6 sh-NSC cells (Figure. 2A).
We determined whether the variation in cell cycle related
proteins induced by WRN deficiency in the two cell lines, reflected
differences in the cell cycle distribution between WRN deficient
cells and their control cells. Under standard growth conditions, the
S phase fraction was much higher in control TK6 cells when
compared to control HL60 cells, approximately 45% versus 30%
respectively (Figure. 2B). This is consistent with the fact that the
doubling time for the TK6 cells is only 14 hours compared to
27 hours for the HL60 cells (Data not shown). The loss of WRN
led to a significant increase in the fraction of HL60 cells in S phase
to 43%, from 32% in HL60 sh-NSC cells, across all time points
(Figure. 2B), indicating an association between the accelerated
proliferation rate in HL60 sh-WRN cells and accelerated DNA
synthesis. In contrast, knocking down WRN in TK6 cells had
very marginal effects, and the cell cycle distribution remained
comparable between WRN deficient TK6 cells and control cells
(Figure. 2B).
HQ exposure enhances DNA damage in WRN deficient
HL60 cells but induces comparable cytotoxicity between
control and WRN deficient HL60 cells
Several lines of evidence support the view that WRN plays
important roles in both unperturbed DNA replication [25,26] and
the response to DNA damage, more specifically the repair of DNA
double-stand breaks (DSBs) via HR [27,28]. We thus treated both
HL60 and TK6 cells with hydroquinone (HQ), a confirmed DSB
inducer [29], as a means to further compare the effects of WRN
deficiency on the response to DNA damage in HL60 and TK6
cells.
Using previously identified non-toxic and mildly toxic concen-
trations of HQ, treatments induced dose-dependent cytotoxicity in
both cell types regardless of WRN status (Figure. 3A). Surprisingly
however, the loss of WRN in HL60 cells resulted in a slight but
significant resistance to HQ toxicity at the highest treatment group
(i.e 20 mM) while the loss of WRN in TK6 cells led to increased
cytotoxicity after HQ treatment at this dose (Figure. 3A). We then
assessed the effects of WRN depletion on DNA damage with or
without HQ treatment using the alkaline COMET assay. Loss of
WRN in HL60 cells induced a significant increase in DNA
damage as measured by % tail DNA, tail intensity and tail
moment in the COMET analysis (Table 1). In contrast, silencing
WRN in TK6 cells had a relatively small effect, as TK6 sh-WRN
cells exhibited only a slightly higher level of endogenous DNA
damage than TK6 sh-NSC cells (Table 2). Furthermore, HQ
treatment in both cell types led to significant and dose-dependent
DNA damage regardless of WRN status (Table 1 & 2). However,
as shown in table 1, all three measured parameters were signifi-
cantly increased in the WRN deficient HL60 cells for all doses. In
contrast, the effects of the loss of WRN in TK6 cells were only
seen in the middle dose group (Table 2).
Further analysis showed that HQ-induced DNA damage led to
a dose-dependent decrease in the number of cells in G1-phase and
an increased number of cells in S and G2 phase in HL60 sh-NSC
cells (Figure. 3B). By contrast, HQ treatment further reduced the
cells in G1 phase and resulted in a dose-dependent increase of G2
phase in HL60 sh-WRN cells, but did not alter the proportion of
cells in S phase (Figure. 3B). As the primary role of activated p53 is
to inhibit the progression from G1 to S phase in the presence of
DNA damage [30], it was suspected that the deficiency of p53 in
WRN Depletion and Cancer
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HL60 cells would result in the loss of this checkpoint function in
the G1-S phase, which was supported by our results (Figure. 3B)
and reinforced by the changes in the cell cycle checkpoint protein
levels (Figure. 3C). The decreased fraction of cells in G1 phase was
associated with increased levels of cRB and E2F1 (Figure. 3C),
thus signaling the ability to undergo replication despite the
presence of DNA-damage in HL60 cells. As WRN is required for
correct recovery of DNA damage induced during S-phase of the
cell cycle [31], an increased G2 phase companied with an
hyperphosphorylated CDC2 (Figure. 3C) indicates the failure of
cells to protect genomic integrity during DNA replication [32].
In TK6 cells, DNA damage induced by HQ treatment led to a
dose-dependent increase in the fraction of cells in G1 phase and a
decreased fraction in S phase in both TK6 sh-NSC and TK6
sh-WRN cells, as the suppression of WRN did not alter the
distribution of cells in each cell cycle phase (Figure. 3D). The cell
cycle pattern results seen in TK6 cells were well reinforced by the
activated p53 regulated G1/S phase cell cycle checkpoint
pathway, which apparently was not affected by the loss of WRN
(Figure. 3E).
Loss of WRN activates the Rad51-HR repair pathway and
leads to DNA damage disrepair and elevated
chromosomal aberrations in HL60 cells
We measured phosphorylated H2AX levels, a marker of DNA
DSBs and an essential component of DSB repair machinery [33],
in both WRN knockdown and control cells, after HQ treatment.
As shown in Figure 4A, a dose-dependent increase in cH2AX
Figure 1. Knockdown of WRN expression in HL60 and TK6 cells leads to altered cell proliferation rates. (A) Immunoblot analysis shows
the specific decrease of WRN protein in HL60 and TK6 cells transduced with shRNA constructs targeting WRN. (B) WRN levels were measured and
normalized to b-actin. The values presented are mean + SE (n = 3) and ** indicates p value ,0.01. (C & D) WRN deficient HL60 and TK6 cells and their
relative control cells were cultured over a seven-day period and cell proliferation rates were evaluated using a hemocytometer and the trypan blue
exclusion assay. Total cell numbers were plotted against day of initiation. In contrast to HL60 sh-WRN cells that displayed a significantly accelerated
proliferation rate (Panel C, Adapted from Ren et al., 2009), the proliferation rate of TK6 sh-WRN cells was slightly decreased (Panel D). The data
represents the average of three independent experiments, in which a trend test was performed (p,0.01).
doi:10.1371/journal.pone.0014546.g001
WRN Depletion and Cancer
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levels was observed in all measured cells 24 hours after HQ
exposure. However, cH2AX levels were higher in the WRN
deficient cells, particularly the HL60 cells (Figure. 4A), in which
cH2AX was detected even at the lowest dose of HQ.
The HR signaling pathway, in which WRN is involved, is
highly regulated and dependent on RAD51 [34] and its
interactions with a number of other co-factors such as WRN,
BLM, p53, etc. to maintain genomic stability [35]. We showed
that loss of WRN in HL60 cells leads to a dramatic increase in
RAD51 and BLM protein levels regardless of HQ treatment
(Figure. 4 A&B), suggesting that HR is constitutively elevated in
response to the increased DSBs in WRN deficient HL60 cells and
may be occurring through compensation mediated by another
helicase, BLM. However, the protein levels of nuclear RAD51
and BLM were slightly reduced in the TK6 cells, and HQ
treatment resulted in no changes on either RAD51 or BLM levels
(Figure. 4 A&B).
WS is a classic chromosomal instability syndrome, and cells
isolated from WS patients demonstrate increased chromosomal
aberrations [36,37,38]. A higher frequency of HR has been
implicated in inducing chromosomal aberrations, and thus
carcinogenesis [39,40]. As demonstrated in Figure 4C, elevated
levels of HR in WRN deficient HL60 cells resulted in increased
levels of chromosomal damage repair, completely changing the
cytogenetic characteristics of HL60 cells, and resulting in both the
disappearance of the characteristic double minutes and the
reduction in the total number of cells with abnormal chromosomal
numbers (Figure. 4 C&D and Figure. S1). As such, aneuploidy was
not as prevalent in WRN deficient HL60 cells as compared to
control cells (Figure. 4D). Interestingly, HQ treatment also led to
effects similar to WRN deficiency, such as a dose-dependent
reduction of double minute chromosomes and aneuploid cells
(Figure. S1 and Table S1). Both effects may be related to the
reduction of WRN levels as indicated by the reduction of WRN
Figure 2. Silencing WRN increases cRB protein level and changes the cell replication rate in HL60 cells. (A) Total cell lysates from HL60
sh-WRN, HL60 sh-NSC, TK6 sh-WRN and TK6 sh-NSC cells were subjected to immunoblot analysis with indicated antibodies. Western blots are
representative of three independent experiments. (B) Quantification analysis of the cell cycle distribution was performed by flow cytometric based
methods. WRN loss increased the fraction of HL60 cells in S phase from 32% in HL60 sh-NSC cells to approximately 43% in HL60 sh-WRN cells across
all time points. In contrast, the cell cycle distribution remained comparable between WRN deficient TK6 cells and control cells.
doi:10.1371/journal.pone.0014546.g002
WRN Depletion and Cancer
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Figure 3. SilencingWRN leads to a differential response to HQ treatment between HL60 and TK6 cells. (A) Cells were exposed to HQ for
24 hours and the cell number and viability were calculated using a hemocytometer and the trypan blue exclusion assay. (B) Cell cycle analysis
showed HQ exposure induced a dose-dependent decrease of G1-phase and an increase of cells in S and G2 phase in HL60 sh-NSC cells. In contrast,
WRN Depletion and Cancer
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levels with increasing HQ doses in control cells (Figure. 4A).
However, we also observed that loss of WRN in HL60 cells
resulted in increased amounts of structural chromosomal aberra-
tions when compared to control HL60 sh-NSC cells (Table S1).
Similarly, HL60 sh-WRN cells displayed a higher frequency of
sister chromatid exchange (SCE) than the HL60 sh-NSC cells
(Figure. 4 E&F). The frequency of SCE averaged to be 3.6 SCE
per cell in HL60 sh-WRN cells versus 2.3 SCE per cell in the
HL60 sh-NSC cell (Data not shown). Sister chromatid exchange
(SCE) has been linked to disrepair resulting from the imbalance of
HR activity [41,42]. In contrast, WRN deficiency alone had little
effect in TK6 cells in terms of the non-banding chromosomal
analysis. Rather, corresponding with the impaired HR activity
resulting from HQ treatment in TK6 cells, the amount of
abnormal chromosomal structures increased with HQ treatment
(Table S1), implying decreased activation of repair mechanisms.
Discussion
WRN deficiency in WS patients leads to rare premature aging
syndromes associated with an excess of unusual cancer types [7,43]
including soft tissue sarcomas, thyroid cancers, and meningiomas
[44]. As the mechanism of how WRN mutations lead to cancer in
WS patients is still not entirely understood, researchers continue to
pursue a better understanding of how these cancers evolve. We
were especially interested in understanding how WRN deficient
cells are able to overcome their characteristic slower proliferation
rate [15,16] and induce tumorigenicity [7,44].
We previously reported that acute silencing of WRN signifi-
cantly accelerated the growth rate of HL60 cells [19]. Although an
in vivo study reported that the loss of WRN in p53 null background
mice led to rapid tumorigenesis [20], this is the first time to our
knowledge that the silencing of WRN has been shown to promote
cell growth in vitro. Here, we show that the loss of WRN leads to a
dramatic increase in the growth rate of p53-deficient HL60 cells
(Figure. 1), while its loss in TK6 cells leads to a decreased
proliferation rate consistent with other WRN deficient cell lines
[15,16]. Under normal culturing conditions, TK6 cells grow faster
than HL60 cells, consistent with the observation that the majority
of control TK6 cells were in the replication phase (S phase), while
the majority of the HL60 cells were in G1 phase (Figure. 2). Loss of
WRN in HL60 cells resulted in a significantly increased fraction of
cells in S phase, suggesting that the rapid accumulation of cells in
replication phase and the distinct cell cycle distribution pattern
contributed to the increased proliferation rate in WRN deficient
HL60 cells.
Eukaryotic cells have evolved a collection of complex networks
for the regulation of the cell cycle, in which cell cycle checkpoints
are crucial to preventing cells with damaged DNA from
proceeding to the next phase, allowing verification of necessary
phase processes, and repairing DNA damage [45]. Dysregulation
of the cell cycle components may cause the cell to uncontrollably
multiply or lead to tumorigenesis. While there are several
checkpoints within the cell cycle, the G1/S transition is the rate-
limiting step that plays a central role in deciding whether the cell
should divide, delay division, or enter a quiescent stage, which in
turn determines the cell proliferation rate. P53 and RB are
essential for the G1/S cell cycle checkpoint [46,47]. As expected,
the p53 mediated DNA repair pathway was activated in response
to increased spontaneous DNA damage in WRN deficient TK6
cells, which resulted in delayed progression of cells into S phase
such that slower population growth followed. In contrast, in HL60
cells, the data not only confirmed that p53 regulated G1/S
checkpoint proteins were deficient, but also demonstrated that
the loss of WRN confers a dramatic increase in the level of
phosphorylated RB (Figure. 2) and thus progression into S phase.
Under normal conditions, most cell types cycle through
replication maintaining a consistent rate through each phase of
the cycle. Of great importance in regulating this rate is the RB
protein, which serves as the gatekeeper of the restriction point (R)
during the late G1 phase. If this discrete check point is interrupted,
the cells lose their most important control mechanism for
inhibiting unwanted proliferation [48]. As seen in our study, the
increased levels of cRB led to the release of E2F1, a transcription
factor that both induces the synthesis of S phase associated
proteins and drives the G1/S phase transition, and unregulated
accelerated proliferation of HL60 sh-WRN cells. We further
showed that increased protein levels of cyclin D3 might be
contributing to the elevated cRB level, but we are unsure if this is
the sole protein responsible for the increase. Moreover, our data
Table 1. DNA damage in HL60 cells treated with HQ for 6 hours analyzed by COMET assay.
HL60 sh-NSC HL60 sh-WRN
Mean Tail Tail % Tail Tail Tail % Tail
(± STM) Length Moment DNA Length Moment DNA
[HQ]mM 0 1.2260.26 0.1460.04 3.2960.24 1.94**60.22 0.33**60.04 6.10*60.49
10 2.3160.67 0.5060.32 3.4960.39 6.64**61.08 1.35**60.37 9.22**60.74
20 7.9860.94 2.4360.46 9.8160.60 17.30**61.14 4.92**60.42 19.37**60.80
50 10.4660.83 2.7460.29 15.3160.72 24.52**61.26 9.77**60.64 28.43**60.86
Note: Mann-Whitney test was used to compare DNA damage between HL60 sh-WRN cells and HL60 sh-NSC cells (*p value ,0.05, **p value ,0.01).
doi:10.1371/journal.pone.0014546.t001
HQ-induced DNA damage in HL60 sh-WRN cells led to a dose-dependent increase of G2 phase, while the proportion of cells in S phase was
unchanged despite HQ exposure. (C) HQ treatment induces a dose-dependent increase of phosphorylated CDC2, indicating the failure of cells to
protect genomic integrity during DNA replication. Total cell lysates from HL60 sh-NSC and HL60 sh-WRN cells were subjected to immunoblot analysis
with indicated antibodies. Western blots are representative of three independent experiments. (D) HQ treatment led to a dose-dependent increase in
the fraction of cells in G1 phase and decrease in S phase in both TK6 sh-NSC and TK6 sh-WRN cells. (E) HQ-induced DNA damage activated p53
regulated G1/S phase cell cycle checkpoint pathway in TK6 cells. Immunoblot analysis showed that the increase of the protein levels of cp53 and p21
and the decrease of E2F1 and cCDC2 protein levels were observed with HQ exposure, which were not affected by the loss of WRN.
doi:10.1371/journal.pone.0014546.g003
WRN Depletion and Cancer
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suggests that the presence of normal functioning p53 in TK6 cells
may have compensated for the deleterious impacts resulting from
the loss of WRN. This implies that WRN’s effects on DNA repair
and cell cycle stability may be highly modulated by the interaction
with other key proteins, in particular p53 [22,49,50].
WRN plays a role in RAD51-dependent HR DNA repair, in
which WRN is believed to promote intermediate resolution and to
suppress cross-over events [27,51]. This has been thought to be
critical for the role of WRN in the maintenance of genomic stability
[52]. It has been demonstrated previously that WRN physically and
functionally interacts with RAD51 [53] and BLM [54], however,
this is the first time that the loss of WRN has been shown to induce
significant up-regulation of RAD51 and BLM protein levels in an in
vitromodel. While it remains unclear how this occurs, it is likely that
this dramatic increase is related to the accelerated cell proliferation
rate present in WRN deficient HL60 cells as RAD51 is maximally
transcribed during S phase [55,56]. This indicates that a complex
relationship exists between WRN deficiency and HR DNA repair
mechanisms so as to compensate for this loss.
As one of the major DNA repair mechanisms, HR provides
high-fidelity template-dependent DSB repair. If left unrepaired,
DSBs could cause chromosomal loss or cell death. However, if
aberrantly repaired, the result could be much worse, giving rise to
mutations and chromosomal rearrangements that could potential-
ly contribute to cancer development [57]. In WS patients,
increased levels of chromosomal aberrations have been reported
[36,37,38,58,59], suggesting that the loss of balanced HR
regulation may be associated with the development of this disease.
One interesting observation from our study is that the increase in
DNA damage disrepair mediated by elevated HR activity, due to
the loss of WRN, is only observed in HL60 cells but not in TK6
cells. Previous reports noted that DNA DSBs stimulated HR in
p53 mutant cells but not in p53 wild-type cells [60,61], suggesting
that p53 appeared to repress HR [62]. However, further studies
are needed to determine whether the different status of p53 is the
causal reason for the observed differences in HR activity and DNA
damage disrepair between HL60 and TK6 cells. We further
showed that the hyperactivity of HR resulted in a completely
altered karyotype of HL60 sh-WRN cells compared to HL60 sh-
NSC cells such that the characteristic abnormal double minute
chromosomes and aneuploidy typical of HL60 cells were absent in
WRN deficient HL60 cells (Figure. 4). However, the hyper-
activated HR and higher repair rates resulting from the loss of
WRN in HL60 cells led to a higher frequency of SCE, indicating
an increased frequency of disrepair and thus genomic rearrange-
ments and gene mutations. This is of particular importance for
tumorigensis as the loss or inactivation of WRN may accelerate the
mutation of other critical genes, which would thus enhance the
likelihood of cancer. More importantly, this gain of function of
enhanced disrepair rate confers a growth advantage in WRN
deficient HL60 cells lacking sufficient DNA damage response
mechanisms mediated by p53 [63,64]. In addition, previous
studies have shown that WRN involved in Non-homologous end
joining (NHEJ) mediated DSBs repair pathway by interacting with
Ku70/80 [65,66] and XRCC proteins [67]. WRN appears to play
a structural role in optimizing DSBs break repair through the HR
and NHEJ repair pathway [28]. While it is beyond the scope of
this study, further investigation of the status of NHEJ repair
mechanisms in these models is warranted.
A multistep model of carcinogenesis is well accepted, in which
an initial mutation in a key DNA repair or metabolism gene leads
to the accumulation of somatic mutations at a higher frequency.
If these somatic mutations occur in other important tumor
suppressors or pro-oncogenes, the tumorigenic process is initiated
and tumor cells gain the ability to start growing uncontrollably.
Our study of silencing WRN in HL60 and TK6 cells suggests
that this multistep model may accurately illustrate the etiology of
cancer development in WS patients as well as other diseases
related to functional loss of WRN (Figure. 5). WRN has been
proposed as a ‘‘caretaker’’ of the genome [14], and an increased
level of chromosomal aberrations has also been reported in WS
patients [58,59]. Thus, functional loss of WRN would in turn
result in the loss or gain of function of other genes due to the
increased genomic instability. We thus hypothesized that the loss
of WRN together with some of its interacting partners would lead
to rapid proliferation through the interruption of normal cell cycle
regulation, resulting in the upregulation of HR activity and
the induction of more chromosomal aberrations and genomic
instability that may be responsible for the transformation from
precancerous cell to cancerous cell in WS patients. More
importantly, this hypothesis can be applied to WRN deficiency
in general, in which the combination of WRN deficiency and the
functional loss of other critical genes could accelerate this trans-
formation and subsequently promote tumor formation. This is
supported by recent studies that showed association between WRN
polymorphism and risks of cancer development, including, but not
limited to breast, gastric adenocarcinoma and bone and soft tissue
sarcomas [9,10,11,12]. Moreover, due to the role of WRN in
protecting cells against DNA damage, functional loss of WRN in
cells with chemically induced DNA damage, such as with benzene,
may result in uncontrolled replication, which can result in genomic
instability and disease [68,69].
Although this model provides a reasonable description of
WRN’s mechanistic role during the development of cancer, we are
aware of the potential limitations of this study and the need for
further studies. While HL60 and TK6 cells are both hematopoietic
Table 2. DNA damage in TK6 cells treated with HQ for 6 hours analyzed by COMET assay.
TK6 sh-NSC TK6 sh-WRN
Mean Tail Tail % Tail Tail Tail % Tail
(± STM) Length Moment DNA Length Moment DNA
[HQ]mM 0 10.1461.08 3.75**60.43 11.5061.17 9.5360.84 2.4860.31 13.54*60.75
5 14.4161.23 6.8360.81 17.2061.15 19.66**61.34 8.37*60.84 23.68**61.09
10 24.0461.51 10.5860.94 22.8461.24 46.08**61.86 22.42**61.29 33.83**61.24
20 69.2362.48 46.9862.47 58.3461.78 66.7761.44 44.4761.36 61.0760.99
Note: Mann-Whitney test was used to compare DNA damage between TK6 sh-WRN cells and TK6 sh-NSC cells (*p value ,0.05, **p value ,0.01).
doi:10.1371/journal.pone.0014546.t002
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cell lines, p53 status is probably only one of the differences
between them. Thus, while our data suggests a role of p53 status in
the different responses of HL60 and TK6 cells to the silencing of
WRN, we cannot exclude the contribution of additional factors,
given the wide range of interactions that occur between WRN and
other cellular proteins [8,9,10]. To further investigate the role of
p53 in modulating the responses of HL60 and TK6 cells to WRN
deficiency, we are currently conducting experiments to re-
introduce p53 to HL60 sh-WRN cells and to silence p53 in
TK6 sh-WRN cells. With these studies, we aim to determine if the
change in p53 status will leads to a reversal of the effects observed
in this study, e.g. accelerated growth rate and increased number of
chromosomal aberrations induced by highly activated HR in TK6
cells with p53 and WRN double knockdown, and vice versa, in
Figure 4. WRN depletion in HL60 cells leads to hyper-activated HR, DNA damage disrepair and chromosomal aberrations. (A & B)
Representative images of immunoblot analysis performed using antibodies against cH2AX, WRN, BLM in whole cell lysate and RAD51 on nuclear
extracts. Immunoblot analysis showed that accumulation of cH2AX in cells exposed to HQ for 24h in a dose-dependent manner. BLM and RAD51
dramatically increased in HL60 sh-WRN cells compared to HL60 sh-NSC cells regardless of HQ treatment. WRN depletion in TK6 cells slightly reduced
RAD51 protein levels. (C) Double minutes (marked with red circle), the characteristic chromosomal aberration in HL60 cells, were absent in HL60 sh-
WRN cells regardless of HQ treatment. (D) Aneuploidy in WRN deficient HL60 cells resolved to 46 chromosomes versus 44 or 45 typical of control
HL60 cells. (E) Representative images of SCE in HL60 sh-NSC and HL60 sh-WRN cells are shown (marked with arrow). (F) Cells with a higher frequency
of SCE are observed in HL60 sh-WRN when compared to the HL60 sh-NSC cells.
doi:10.1371/journal.pone.0014546.g004
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HL60 cells with a functional p53 protein. However, it is clear that
additional studies using other p53 wild-type/null cell line variants
or cells deficient in other key players, such as RB or its regulators,
are necessary to strengthen our hypothesis.
Materials and Methods
Cell Culture and chemical treatments
Human hematopoietic HL60 and TK6 cells were obtained from
the American Type Culture Collection (Manassas, VA). HL60
cells were grown in IMDM (GIBCO, San Diego, CA) with L-
glutamine and 20% fetal bovine serum (Omega Scientific, San
Diego, CA). TK6 cells were maintained in RPMI 1640 medium
with 10% fetal bovine serum in standard conditions. Hydroqui-
none (Sigma Aldrich, St. Louis, MO) was dissolved in 1XPBS for
all experiments. Cells were treated with 1XPBS and 10, 20, or
50 uM hydroquinone for HL60 cells or 5, 10 and 20 uM
hydroquinone for TK6 cells at a cell density of 4–56105 cells/ml.
Generation of shRNA and retroviral transduction
The detailed design and sequences of WRN shRNA construct
(sh-WRN) and non-target shRNA control (sh-NSC) have been
previously reported [19]. Briefly, lentiviruses were produced by
transfection of 293FT cells with the packaging plasmids along with
the lentiviral shRNA vector, according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). HL60 and TK6 cells were
transduced and put in selection media containing 6 mg/ml and
8 mg/ml of blasticidin respectively 48 hours post-transduction.
Cells resistant to blasticidin were isolated and assayed for protein
expression levels using Western blot analysis.
Cell Proliferation
Control (HL60 sh-NSC and TK6 sh-NSC) and WRN knock
down (HL60 sh-WRN and TK6 sh-WRN) cell lines were seeded at
26105 and allowed to grow under normal conditions. Cells were
enumerated daily for seven days using the trypan blue assay. Cell
Figure 5. A hypothetical etiological model for cancer development related with WRN deficiency. On the basis of this study and outside
literature, a multi-step model for tumor development is proposed in WS patients and other human cell types with reduced functionalities of WRN. We
speculate that either complete or partial loss of function of WRN can lead to both increased genomic instability and an increase of somatic mutation rate,
which in turn can result in an increased susceptibility for the gain or loss of functions of other genes. The functional loss of WRN in combination with a
deficiency in other key regulators of the cell cycle or DNA damage repair pathwaymay result in an accelerated conversion from pre-cancerous to cancerous
cell line, thus allowing for rapid progression of tumorigenesis and cancer formation in WS patients and other diseases related to WRN deficiency.
doi:10.1371/journal.pone.0014546.g005
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proliferation and viability were measured in triplicate in three
independent experiments.
Single-cell gel electrophoresis (COMET)
The alkaline Comet assay was performed as previously
described [70] with some modifications. To observe endogenous
DNA damage, cells were seeded in culture for 3 days and
maintained at a cell density of 56105 cells/ml. Cells were collected
at 6 and 24 h for analysis. To measure chemically induced DNA
damage, cells were seeded as above and exposed to hydroquinone
for 6 h prior to DNA damage analysis. Five hundred randomly
chosen cells per slide were scanned and analyzed automatically
using CometScan imaging software (Metasystems, Germany).
Cells were subsequently screened manually to exclude cells that
did not meet stringent requirements (i.e. poor staining, loss of
focus, or oddly shaped). Mean tail length, moment and percentage
of tail DNA [71], all measurements of total DNA damage, were
calculated for,400 cells. All slides were coded to prevent observer
bias. Non-parametric method Mann-Whitney U test was used to
compare DNA damage between WRN deficient and control cells
(*p value ,0.05, **p value ,0.01).
Cell Cycle Analysis
For analysis of cell cycle, HL60 and TK6 control and WRN
knock down cells were cultured in the same manner as for
COMET analysis. Cells were collected at 6 and 24 h, washed
twice with ice-cold PBS buffer (pH 7.4), fixed with 70% ice-cold
ethanol at 220uC for 15 min, stained with propidium iodide (PI)
(100 mg/ml) and treated with RNase A overnight. In three
independent experiments done in triplicate, at least 16104 cells
were analyzed on a Beckman Coulter EPICS XL-MCL flow
cytometer using System II software. The collected data was then
analyzed by Flowjo software (Ashland, OR 97520).
Immunoblot analysis
Total cell lysates were collected from 56106 cells using 300 uL
of radioimmunoprecipitation assay (RIPA) lysis buffer. Nuclear
extractions were collected using 16107 cells and a nuclear
extraction kit (Millipore, Billerica, MA) according to the
manufacturer’s protocol. Protein concentrations were determined
by the DC assay (Bio-Rad, Hercules, CA). Equal protein amounts
were resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), transferred onto nitrocellulose
membranes, and probed for WRN (Santa Cruz Biotechnology,
Santa Cruz, CA), BLM, RAD51 (Millipore, Billerica, MA),
Phospho-Histone H2A.X (cH2AX), P53 Antibody, Phospho-P53
(cP53), p21 Waf1/Cip1, p27 Kip, CDK2, CDK6, Cyclin E,
Cyclin D3, Phospho-Rb (cRb), Phospho-CDC2 (cCDC2) (Cell
Signaling Technology, Danvers, MA), and b-actin (Sigma-Aldrich,
St. Louis, MO). Proteins were visualized using the enhanced
chemiluminescence (ECL) method per manufacturer’s protocol
(Amersham Biosciences, United Kingdom). Film was exposed and
developed using the Konica SRX-101 developer (Konica Minolta
Medical Imaging USA, Wayne, NJ). Each measured protein
except the nuclear protein RAD51 was normalized to b-actin, the
loading control, and quantified using ImageJ software (NIH,
Bethesda, MD). The Coomassie stain was used according to
manufacturer’s protocol to confirm loading uniformity of nuclear
proteins into the SDS-PAGE gel (Bio-Rad, Hercules, CA), and the
gel was subsequently visualized and photographed (Alpha
Innotech, San leandro, CA). Data obtained is representative of
the averages of at least three independent experiments. Error bars
represent SEM. *, p,0.05; **, p,0.01.
Non-banding chromosome aberration analysis
Colcemid (0.1 mg/ml, Invitrogen, Carlsbad, CA) was added to
each culture 2 hours before harvesting to arrest cells at
metaphase. After hypotonic treatment (0.075 M KCl) for
30 min at 37uC, the cells were fixed three times with freshly
prepared Carnoy’s fixative (methanol: glacial acetic acid = 3:1).
The fixed cells were dropped onto glass slides, allowed to air dry
and stored at 220uC. The cells on the slides were then stained
with Giemsa and metaphase spreads were scanned and localized
automatically using Metafer software (MetaSystems, Altlussheim,
Germany). Metaphases were scored at 10006 magnification
to detect numerical and structural chromosomal aberrations.
Metaphase spreads were considered scorable if the cells appeared
intact with the chromosomes condensed and well spread out as
well as if the centromeres and chromatids were readily visible.
The structural chromosomal aberrations were defined according
to An International System for Human Cytogenetic Nomencla-
ture (2005). All slides for all assays were coded to prevent
observer bias.
Sister-chromatid Exchange Analysis
For SCE analysis, filter sterilized solution of BrdU ((Sigma
Aldrich, St. Louis, MO) was added to fresh culture medium at a
final concentration of 5 mg/ml and the cells were incubated strictly
in the dark for 42 h. Chromosome preparations were then done
according to the procedure described for chromosomal aberration
frequency measurement. After metaphase were prepared, the
slides were incubated 10–15 min strictly in the dark in bisbenzi-
mide H 33258 (Sigma Aldrich, St. Louis, MO) solution (50 mg/
ml), rinsed in phosphate buffered water and incubated in fresh
phosphate buffered water under UV light source for 60 min.
Preparations were rinsed again, incubated for 15 min in preheated
26 SSC at 60uC in the water-bath. After rinsing, preparations
were stained in 4% phosphate buffered Giemsa solution. Fifty
metaphases were evaluated per treatment level. Only fully
differentiated metaphases were evaluated. SCEs were expressed
as SCEs/cell. Non-parametric method Mann-Whitney U test was
used to compare SCE frequencies between WRN deficient and
control cells (*p value ,0.05).
Data Analysis
Statistical analyses of data were performed using one-way
analysis of variance (ANOVA). A trend x2 test was used to
compare cell growth trends between control cells and WRN
knocking down cells. Data obtained is representative of
the averages of at least three independent experiments. Error
bars represent standard error of the mean (SEM). *, p,0.05;
**, p,0.01.
Supporting Information
Figure S1 Rate of double minute positive cells between HL60
sh-NSC and HL60 sh-WRN cells after HQ exposure. The
complete disappearance of the characteristic double minute
chromosomes was seen in WRN deficient HL60 cells regardless
of HQ treatment. HQ treatment alone led to a dose-dependent
reduction of double minute chromosomes in HL60 sh-NSC
cells.
Found at: doi:10.1371/journal.pone.0014546.s001 (0.01 MB TIF)
Table S1 Rate of cells with specific chromosome aberrations
(%).
Found at: doi:10.1371/journal.pone.0014546.s002 (0.04 MB
DOC)
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